Investors
Capitalizing the layer
the system can't see.
AlfredAI is physician-led, EMR-native, and aligned with how CMS already pays for chronic care. Patients live with chronic disease 99% of their lives — we operate that 99%, inside the EMR.
For qualified investors only. Specific round terms, financial projections, and competitive analysis are gated behind a mutual NDA. The public content below is informational, not an offer or solicitation to sell securities.
The market
The $4.1T chronic care gap — and where the new dollars are.
US chronic disease spend — 90% of all healthcare costs (CDC)
of Medicare beneficiaries have 2+ chronic conditions with no coordinated AI
Per-patient CMS billing range, unit economics, and ROI model available in the data room (RPM + CCM + APCM + BHI)
CMS reimbursement figures reflect 2026 fee schedules and represent addressable billing opportunity, not guaranteed revenue. Practice eligibility, patient consent, and time-on-task requirements apply.
Positioning
The empty quadrant: multi-condition × platform model.
Today's chronic-care market is split between single-condition point solutions and generalist telehealth services. AlfredAI is the first multi-condition AI platform that lives inside the EMR — physician-governed, CMS-aligned, and built to scale with the practice rather than around it.
Multi-condition by design
One orchestration framework covers all polyconditions — not nine point products.
Physician-governed
Designed under clinical governance, not retrofitted from a generalist LLM.
CMS-aligned revenue
Practice captures RPM + CCM + APCM + BHI billing currently left on the table.
EMR-native, not parallel
Bidirectional FHIR R4 writeback to six leading EMRs. No new login, no shadow chart.
Specific competitor names, valuations, and side-by-side analysis are available under NDA.
Preliminary clinical evidence
Grounded where it matters most: the patient.
| Endpoint | Result | Study |
|---|---|---|
| Patient knowledge score (AFib) | 72.8% → 88.4% (p<0.001), preliminary | IRB-approved prospective study |
| Medication adherence target | +35% target (enrolling) | RCT in collaboration with University of Adelaide |
| Response consistency | Consistent, patient-grade output | Internal benchmarking |
| Readability (Flesch–Kincaid) | Patient-grade across conditions | Internal benchmark |
All clinical data is preliminary and not intended as evidence of safety or efficacy. AlfredAI is not FDA cleared. AFib validation demonstrates the core AI capability; the platform architecture is condition-agnostic and extends to all nine supported conditions.
Round terms, financials, and competitor analysis available to qualified investors under NDA.
AlfredAI is selectively engaging with mission-aligned healthcare and AI investors. Specific SAFE terms, financial projections, use-of-funds breakdown, and named competitive analysis are shared after a counter-signed mutual NDA.
This page is for informational purposes only and does not constitute an offer to sell securities.